[1]

Ruopp NF, Cockrill BA. 2022. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA 327:1379−1391

doi: 10.1001/jama.2022.4402
[2]

Tuder RM. 2009. Pathology of pulmonary arterial hypertension. Seminars in Respiratory and Critical Care Medicine 30:376−385

doi: 10.1055/s-0029-1233307
[3]

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, et al. 2013. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 62:D34−D41

doi: 10.1016/j.jacc.2013.10.029
[4]

Humbert M, Sitbon O, Guignabert C, Savale L, Boucly A, et al. 2023. Treatment of pulmonary arterial hypertension: recent progress and a look to the future. The Lancet Respiratory Medicine 11:804−819

doi: 10.1016/s2213-2600(23)00264-3
[5]

Mandras SA, Mehta HS, Vaidya A. 2020. Pulmonary hypertension: a brief guide for clinicians. Mayo Clinic Proceedings 95:1978−1988

doi: 10.1016/j.mayocp.2020.04.039
[6]

Thenappan T, Ormiston ML, Ryan JJ, Archer SL. 2018. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360:j5492

doi: 10.1136/bmj.j5492
[7]

Beshay S, Guha A, Sahay S. 2021. Evaluation, diagnosis, and classification of pulmonary hypertension. Methodist DeBakey Cardiovascular Journal 17:86−91

doi: 10.14797/ocdf4453
[8]

Zhang C, Song Z, Zhao Y, Guo X, Huang T, et al. 2025. The underexplored pulmonary toxicity of pyrrolizidine alkaloids: emerging hazard from food contamination. Chemico-Biological Interactions 420:111709

doi: 10.1016/j.cbi.2025.111709
[9]

Schrenk D, Gao L, Lin G, Mahony C, Mulder PPJ, et al. 2020. Pyrrolizidine alkaloids in food and phytomedicine: occurrence, exposure, toxicity, mechanisms, and risk assessment - a review. Food and Chemical Toxicology 136:111107

doi: 10.1016/j.fct.2019.111107
[10]

Brugnerotto P, Silva B, Gonzaga LV, Costa ACO. 2025. Comprehensive review of pyrrolizidine alkaloids in bee products: occurrence, extraction, and analytical methods. Food Chemistry 483:144211

doi: 10.1016/j.foodchem.2025.144211
[11]

Zhang C, Huang T, Guo X, Cui X, He Y. 2026. Hemolysis-associated disorder and natural product exposures: underrecognized drivers of an escalating global pulmonary arterial hypertension burden—an ecological study of 204 countries and territories. Future Integrative Medicine 1–17

doi: 10.14218/FIM.2026.00004
[12]

Hill NS, Gillespie MN, McMurtry IF. 2017. Fifty years of monocrotaline-induced pulmonary hypertension: what has it meant to the field? Chest 152:1106−1108

doi: 10.1016/j.chest.2017.10.007
[13]

Zhang C, Huang T, Guo X, Fan Y, Song Z, et al. 2026. Hemoglobin adduction and impaired oxygen transport define the etiology of pyrrolizidine alkaloid-induced pulmonary arterial hypertension. Phytomedicine 152:157847

doi: 10.1016/j.phymed.2026.157847
[14]

Solinc J, Ribot J, Soubrier F, Pavoine C, Dierick F, et al. 2022. The platelet-derived growth factor pathway in pulmonary arterial hypertension: still an interesting target? Life 12:658

doi: 10.3390/life12050658
[15]

Amelirad A, Shamsasenjan K, Akbarzadehlaleh P, Pashoutan Sarvar D. 2019. Signaling pathways of receptors involved in platelet activation and shedding of these receptors in stored platelets. Advanced Pharmaceutical Bulletin 9:38−47

doi: 10.15171/apb.2019.005
[16]

Estevez B, Du X. 2017. New concepts and mechanisms of platelet activation signaling. Physiology 32:162−177

doi: 10.1152/physiol.00020.2016
[17]

Pullamsetti SS, Savai R, Seeger W, Goncharova EA. 2017. Translational advances in the field of pulmonary hypertension. From cancer biology to new pulmonary arterial hypertension therapeutics. Targeting cell growth and proliferation signaling hubs. American Journal of Respiratory and Critical Care Medicine 195:425−437

doi: 10.1164/rccm.201606-1226PP
[18]

Cai B, Yang L, Do Jung Y, Zhang Y, Liu X, et al. 2022. PTEN: an emerging potential target for therapeutic intervention in respiratory diseases. Oxidative Medicine and Cellular Longevity 2022:4512503

doi: 10.1155/2022/4512503
[19]

Song Z, Lian W, He Y, Zhang C, Lin G. 2023. Targeting erythrocyte-mediated hypoxia to alleviate lung injury induced by pyrrolizidine alkaloids. Archives of Toxicology 97:819−829

doi: 10.1007/s00204-023-03443-1
[20]

Ma J, Ruan J, Chen X, Li D, Yao S, et al. 2019. Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chemical Research in Toxicology 32:1027−1039

doi: 10.1021/acs.chemrestox.8b00369
[21]

Offermanns S. 2006. Activation of platelet function through G protein–coupled receptors. Circulation Research 99:1293−1304

doi: 10.1161/01.Res.0000251742.71301.16
[22]

Bye AP, Unsworth AJ, Gibbins JM. 2016. Platelet signaling: a complex interplay between inhibitory and activatory networks. Journal of Thrombosis and Haemostasis 14:918−930

doi: 10.1111/jth.13302
[23]

Green DE, Sutliff RL, Hart CM. 2011. Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension? Pulmonary Circulation 1:33−47

doi: 10.4103/2045-8932.78101
[24]

Mahimainathan L, Choudhury GG. 2004. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. Journal of Biological Chemistry 279:15258−15268

doi: 10.1074/jbc.M314328200
[25]

Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. 2004. UniProt: the universal protein knowledgebase. Nucleic Acids Research 32:D115−D119

doi: 10.1093/nar/gkh131
[26]

McGarvey PB, Nightingale A, Luo J, Huang H, Martin MJ, et al. 2019. UniProt genomic mapping for deciphering functional effects of missense variants. Human Mutation 40:694−705

doi: 10.1002/humu.23738
[27]

Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, et al. 2006. Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone. International Journal of Cancer 118:2390−2398

doi: 10.1002/ijc.21799
[28]

Kato S, Ohnuma N, Ohno K, Takasaki K, Okamoto S, et al. 1997. Changes in sequestered leukocytes and platelets in the pulmonary microvasculature of rats with monocrotaline-induced pulmonary hypertension. International Journal of Microcirculation: Clinical and Experimental 17:290−297

doi: 10.1159/000179243
[29]

Hu XS, Du CQ, Zeng CL, Yao L, Zhang FR, et al. 2010. Systemic evaluation of platelet and leukocyte activation and interaction in a rat model of pulmonary arterial hypertension. Cardiology 117:44−53

doi: 10.1159/000320107
[30]

Ono S, Voelkel NF. 1991. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. Journal of Applied Physiology 71:2483−2492

doi: 10.1152/jappl.1991.71.6.2483
[31]

Zhu Y, Shu D, Gong X, Lu M, Feng Q, et al. 2022. Platelet-derived TGF (transforming growth factor)-β1 enhances the aerobic glycolysis of pulmonary arterial smooth muscle cells by PKM2 (pyruvate kinase muscle isoform 2) upregulation. Hypertension 79:932−945

doi: 10.1161/hypertensionaha.121.18684